Article
A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review.
Pathology, research and practice - 1 Jul 2024
Liu Ying, Li Mingyang, Guo Yu, Zhang Zhiyong, Du Liuyang, Zhang Xiaotong, Wang Yingping, Zhang Dong, Xue Lingfei, Lei Binhua, Su Jing, Zhang Ruiwen, Chen Jiaohong, Zhang Xiangqian, Jia Qingge, Tian Chuntao
Abstract excerpt
BACKGROUND: Targeted therapy with combined dabrafenib and trametinib has been proven to provide clinical benefits in patients with BRAF V600E mutation-positive NSCLC. Nevertheless, the treatment strategy for NSCLC patients with BRAF non-V600E mutations remains limited. CASE PRESENTATION: Here, we present a NSCLC patient with a BRAF N581S mutation, which is a class III BRAF mutation, and this patient had a durable...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.